



# Hymecromone and Its Products as Cytotoxic Candidates for Brain Cancer: A Brief Review

Yasser Fakri Mustafa<sup>1\*</sup>, Noora Thamer Abdulaziz<sup>2</sup>

## Abstracts

Brain cancer is the 10<sup>th</sup> cause of death among patients suffering from cancer worldwide. Despite the huge effort put out to extract, design, and synthesize novel chemotherapeutic drugs, medicinal chemists continue to face significant obstacles due to considerable side effects, growing tumor resistance, and poor selectivity. In recent decades, great attention has been paid to the anti-cancer potential of a variety of natural compounds. Coumarin-based compounds, for example, are distinguished by their structural variety and wide range of pharmacological characteristics. Among these, hymecromone, also known as 7-hydroxy-4-methylcoumarin, and its derivatives have shown promise in the treatment of multi-drug cancer resistance, the decrease of chemotherapeutic drug side effects, and the creation of photo-directed cancer therapy. Furthermore, numerous synthetic hymecromone-derived compounds have been demonstrated to have a broad antitumor potential, making them effective against a variety of cancers including leukemia, prostate cancer, lung cancer, breast cancer, and brain cancer. In this review article, the authors evaluated the findings of a number of recently published scientific studies in order to emphasize the structural properties of hymecromone-derived compounds that are crucial in their potential as antitumor agents for brain cancer. The specification of these qualities might help guide future research towards the design and synthesis of newer chemotherapeutic drugs with improved features. 175

**Key Words:** Brain Cancer, Hymecromone, Derivatization, Synthetic Coumarins, 7-hydroxy-4-Methylcoumarin.

**DOI Number:** 10.14704/nq.2021.19.7.NQ21101

**NeuroQuantology 2021; 19(7):175-186**

## Introduction

Interest has directed in the last decades toward a characteristic family of the natural and synthetic products belonged to the benzo- $\alpha$ -pyrone class named coumarins (Akkol et al., 2020). This interest has based on the broad spectrum of their pharmacological potentials (Aldewachi et al., 2020) as well as their industrial applications (A.M. Nejres et al., 2020; Aws Maseer Nejres et al., 2020). Coumarin-based products can be isolated from different natural sources (Mustafa et al., 2020b) and also synthesized by various chemical reaction phenotypes (Mustafa et al., 2020c, 2020a). Many of these products exhibited numerous biological effects such as anticancer (Mustafa et al., 2020d), antimicrobial (Mohammed and Mustafa, 2020),

antioxidant (Khalil and Mustafa, 2020), anti-inflammatory (Oglah et al., 2020b; Oglah and Mustafa, 2020a), anti-aggregation (Moath Kahtan Bashir et al., 2020), and cardio-protective (Prabhu et al., 2006) activities. Concerning the antitumor activity, coumarin-derived products can exert this effect by various documented mechanisms (Oglah and Mustafa, 2020b). This relying on the substitutional pattern of the coumarin core structure (Oglah et al., 2020a).

**Corresponding author:** Yasser Fakri Mustafa

**Address:** <sup>1\*</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Nineveh, Iraq; <sup>2</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Nineveh, Iraq.

<sup>1\*</sup>E-mail: Dr.yassermustafa@uomosul.edu.iq, <http://orcid.org/0000-0002-0926-7428>

**Relevant conflicts of interest/financial disclosures:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Received:** 19 May 2021 **Accepted:** 26 June 2021



Hymecromone that commonly known as 7-hydroxy-4-methylcoumarin is one of the most interested and evaluated coumarins (Moath Khtan Bashir et al., 2020). The chemical backbone of hymecromone, as depicted in Figure 1, has utilized as a pharmacological scaffold to prepare a large number of derived products and subsequently investigate their medicinal activities (Mustafa, 2019). Among them, the antitumor potential of hymecromone-derived products has been widely investigated by many scientists, and the results of

their investigations have been recorded in many scientific papers (Bashir et al., 2021; Kumar et al., 2015; Mahmood et al., 2014; Mustafa et al., 2021b, 2021c, 2021a, 2018; Mustafa and Abdulaziz, 2021a, 2021b). This incites the team-work for reporting this review to highlight the characteristic features of hymecromone-derived products that mediate their antitumor activity. Also, this review may facilitate the choice of a proper substitutional pattern by medicinal chemists to optimize such activity of these products.




Figure 1. Chemical backbone of hymecromone

Bhattacharyya *et al.* have investigated the consequence of utilizing hymecromone for managing the skin tumor-excited in mice. This investigation revealed that hymecromone has a beneficial role in the expression and regulation of many signal-related proteins. Such proteins as Caspase-3, Caspase-9, IL-6, Cytochrome-c, NF-kB Apaf, PCNA, Bax, Akt, Aryl hydrocarbon receptor, Bad, Bcl-2, Bcl-xL, and p53. The authors concluded that this coumarin-derived product down-regulated the pro-apoptotic proteins as well as up-regulated the apoptotic proteins. Based on these findings, this product may offer a new template for designing and synthesizing specific

agents for the treatment of this cancer phenotype (Bhattacharyya et al., 2009).

Ibrahim *et al.* have recorded the preparation of three hymecromone derivatives complexed with copper. The antitumor potential of these complexes, herein symbolized as **N1-N3** (Figure 2), was evaluated against two cancer lines including MCF-7 belonged to the breast cancer, and A549 belonged to the lung cancer. The results exhibited that the products **N1** and **N2** showed a potent activity toward the first cancer line, while **N3** displayed a powerful inhibitory effect on the second cancer line (Jumal et al., 2015).





Figure 2. Chemical backbones of the hymecromone derivatives complexed with copper as displayed by Ibrahim *et al.*



Yelchuri *et al.* have recorded the preparation of ten coumarin-derived products by conjugating hymecromone with various benzyl, allyloxy, acrylic acid, fatty acid, and acrylonitrile analogues, as shown in Scheme 1. These hymecromone-derived products, herein symbolized as **N4-N13**, have been evaluated as potential antitumor agents against four cancer cell lines. These cell lines included

MDA-MB 231 (Human breast cancer), SKOV3 (Ovarian cancer), HepG2 (Hepatocellular carcinoma), and DU145 (Prostate carcinoma). The results exhibited that the synthesized conjugates revealed an encouraging antitumor potential with supremacy effects contributed to products **N4** and **N8** (Yelchuri et al., 2016).




177

**Scheme 1.** Synthetic plan of the hymecromone-derived conjugates as reported by Yelchuri *et al.*

Kawase *et al.* have investigated the potential of 44 coumarin-derived products as modulators for cancer-resistance toward cytotoxic drugs. These products, herein symbolized **N14-N57** (Figure 3), showed a good selectivity toward tumor cells in comparison with normal ones. Also, products **N56** and **N57** exhibited a powerful anticancer activity. The authors concluded that these

coumarin-derived products may account for new modulators of cancer cell-resistance with minimal toxicity against normal cells. In addition, there is a correlation between the chemical structures of these products and their modulating impact, this may contribute to the synthesis of optimal cytotoxic products (Kawase et al., 2005).




| Compd | R <sup>1</sup>                                | R <sup>2</sup>                                  | R <sup>3</sup>   | R <sup>4</sup>   | R <sup>5</sup>                   | R <sup>6</sup> |
|-------|---|---|------------------|------------------|----------------------------------|----------------|
| 1     | H   | H   | H                | H                | H                                | H              |
| 2     | H   | H   | H                | H                | OH                               | H              |
| 3     | H   | H   | H                | OH               | OH                               | H              |
| 4     | H   | H   | H                | OCH <sub>3</sub> | OH                               | H              |
| 5     | H   | H   | OCH <sub>3</sub> | OCH <sub>3</sub> | OH                               | H              |
| 6     | H   | CH <sub>3</sub>                                 | H                | H                | OH                               | H              |
| 7     | H   | CH <sub>3</sub>                                 | H                | OH               | H                                | H              |
| 8     | H   | CH <sub>3</sub>                                 | H                | OH               | OH                               | H              |
| 9     | H   | CH <sub>3</sub>                                 | OH               | H                | OH                               | H              |
| 10    | H   | CH <sub>3</sub>                                 | H                | OH               | OCH <sub>3</sub>                 | H              |
| 11    | H   | CH <sub>3</sub>                                 | H                | OCH <sub>3</sub> | OH                               | H              |
| 12    | H   | CH <sub>3</sub>                                 | H                | H                | OCH <sub>3</sub>                 | H              |
| 13    | H   | CH <sub>3</sub>                                 | H                | OCH <sub>3</sub> | H                                | H              |
| 14    | CH <sub>3</sub>                               | H   | H                | H                | OH                               | H              |
| 15    | CH <sub>3</sub>                               | CH <sub>3</sub>                                 | H                | H                | OH                               | H              |
| 16    | CH <sub>3</sub>                               | CH <sub>3</sub>                                 | H                | OH               | OH                               | H              |
| 17    | CH <sub>3</sub>                               | CH <sub>3</sub>                                 | H                | OH               | OCH <sub>3</sub>                 | H              |
| 18    | CH <sub>3</sub>                               | CH <sub>3</sub>                                 | H                | OCH <sub>3</sub> | OH                               | H              |
| 19    | CH <sub>3</sub>                               | CH <sub>3</sub>                                 | H                | H                | OCH <sub>3</sub>                 | OH             |
| 20    | -(CH <sub>2</sub> ) <sub>3</sub> -            |   | H                | OH               | OH                               | H              |
| 21    | -(CH <sub>2</sub> ) <sub>3</sub> -            |   | OH               | H                | OH                               | H              |
| 22    | -(CH <sub>2</sub> ) <sub>3</sub> -            |   | H                | OH               | OCH <sub>3</sub>                 | H              |
| 23    | -(CH <sub>2</sub> ) <sub>3</sub> -            |   | H                | OCH <sub>3</sub> | OH                               | H              |
| 24    | -(CH <sub>2</sub> ) <sub>4</sub> -            |   | H                | OH               | OCH <sub>3</sub>                 | H              |
| 25    | -Benzo-                                       |   | H                | NO <sub>2</sub>  | H                                | H              |
| 26    | H   | CH <sub>2</sub> CO <sub>2</sub> H               | H                | H                | OCH <sub>3</sub>                 | H              |
| 27    | NO <sub>2</sub>                               | OH  | H                | H                | H                                | H              |
| 28    | CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> | H   | H                | H                | H                                | H              |
| 29    | H   | Ph  | H                | OH               | OCH <sub>3</sub>                 | H              |
| 30    | Ph  | CH <sub>3</sub>                                 | H                | OH               | OCH <sub>3</sub>                 | H              |
| 31    | H   | CF <sub>3</sub>                                 | H                | OH               | OCH <sub>3</sub>                 | H              |
| 32    | H   | CF <sub>3</sub>                                 | H                | H                | N(CH <sub>3</sub> ) <sub>2</sub> | H              |
| 33    | CH <sub>3</sub>                               | CH <sub>3</sub>                                 | H                | OR               | OH                               | H              |
| 34    | (CH <sub>2</sub> ) <sub>2</sub> OH            | CH <sub>3</sub>                                 | H                | OH               | OCH <sub>3</sub>                 | H              |
| 35    | (CH <sub>2</sub> ) <sub>2</sub> OH            | CH <sub>3</sub>                                 | H                | H                | OH                               | OH             |
| 36    | (CH <sub>2</sub> ) <sub>2</sub> OH            | CH <sub>3</sub>                                 | H                | OCH <sub>3</sub> | OH                               | H              |
| 37    | (CH <sub>2</sub> ) <sub>2</sub> OH            | CH <sub>3</sub>                                 | OH               | H                | OH                               | H              |
| 38    | H   | CH <sub>2</sub> CO <sub>2</sub> CH <sub>3</sub> | H                | OH               | OCH <sub>3</sub>                 | H              |
| 39    | CH <sub>3</sub>                               | CH <sub>3</sub>                                 | H                | OH               | OC <sub>2</sub> H <sub>5</sub>   | H              |
| 40    | H   | C <sub>3</sub> H <sub>7</sub>                   | H                | OH               | OCH <sub>3</sub>                 | H              |
| 41    | H   | CH(CH <sub>3</sub> ) <sub>2</sub>               | H                | OH               | OCH <sub>3</sub>                 | H              |
| 42    | C <sub>4</sub> H <sub>9</sub>                 | CH <sub>3</sub>                                 | H                | OH               | OCH <sub>3</sub>                 | H              |
| 43    | CH(CH <sub>3</sub> ) <sub>2</sub>             | CH <sub>3</sub>                                 | H                | OH               | OCH <sub>3</sub>                 | H              |
| 44    | C <sub>2</sub> H <sub>5</sub>                 | CH <sub>3</sub>                                 | H                | OH               | OCH <sub>3</sub>                 | H              |

Figure 3. Chemical structures of the coumarin-derived products that prepared by Kawase et al. as modulators for cancer-resistance

Musa *et al.* have investigated the mechanism of the antitumor potential for nine coumarin-derived products including hymecromone. This evaluation was performed by using crystal violet-dependent assay on two cancer lines, which are MDA-MB-231 (breast cancer) and PC-3 (prostate cancer). These products, herein symbolized as **N58-N66** (Figure 4), exhibited a promising effect against the test cancerous lines with a notability attributed to

product **N63**. The authors concluded that the antitumor mode of action of the product **N63** involved the loss of mitochondrial membrane potential, arrest of the cell-cycle at phase at G<sub>0</sub>/G<sub>1</sub>, enhancement of the generation of the reactive oxygen species, deprivation in the GSH level, and induction of apoptosis by activating the intrinsic pathway (Musa, 2017).






**Figure 4.** Chemical backbones of the coumarin-derived products investigated for their antitumor activity by Musa *et al.*

Li *et al.* have prepared a panel of ten new coumarinyl- $\alpha$ -aminophosphonate products, as displayed in Scheme 2. The anticancer effect of these products was investigated against three human cancerous lines, which were KB (human nasopharyngeal carcinoma), MGC-803 (lung adenocarcinoma), and HCT-116 (colorectal). The

results indicated that these novel products, herein symbolized **N67-N76**, have a better antitumor activity than that of hymecromone, and among these products, **N76** showed the best effect (Li *et al.*, 2015).




**Scheme 2.** Synthetic plan of new coumarinyl- $\alpha$ -aminophosphonate products which synthesized by Li *et al.*

Tao *et al.* have recorded the preparation of 4 multi-functional products, as displayed in Scheme 3. The chemical backbones of these products have derived from three units named phenyl butyric acid, hymecromone, and magnolol. The anticancer potential of these molecules was examined against four cancerous lines including MCF-7, A549, HepG2, and A431. The results exhibited that the product **N80** has a better effect in comparison with those of


its precursors. Besides, this product presented other advantages such as the long duration of effect, and the possibility of *in vivo* monitoring owing to its fluorescent characteristic. The authors concluded that the product **N80** offered a promising scaffold to design and synthesize more potent derivatives related to magnolol (Tao *et al.*, 2019).





**Scheme 3.** Synthetic plan of the phenyl butyric acid-coumarin-magnolol derivatives named N77-N80


Nikalje *et al.* have recorded the preparation of piperazinyl-coumarin conjugates using the chemical core of hymecromone as a building unit. The cytotoxicity of these hybridized molecules, herein symbolized as **N81** and **N82** (Figure 5), versus three cancerous lines including MCF-7, HeLa, and NCI-H226 has been tested. The results indicated that the product **N81** has a powerful inhibitory potential versus MCF-7 and HeLa compared with adriamycin as a standard cytotoxic drug and moderate inhibitory potential against NCI-H226 (Ostrowska, 2020).



**Figure 5.** Chemical backbones of the piperazinyl-coumarin conjugates synthesized via Nikalje *et al.*

Benitez *et al.* have reported that the synchronous administration of hymecromone with sorafenib enhanced the anti-angiogenesis potential of the last agent resulting in the reduction of capillary generation, proliferation, and invasion of renal carcinoma cells. Besides, this incorporation may enhance apoptosis in this type of cancerous cells 8-fold than that of sorafenib alone. The main advantage arisen from such incorporation is the reduction of hyaluronic acid (HA) synthesis. This may be opposite by adding HA to the proposed schedule of therapy (Benitez *et al.*, 2013; Saito *et al.*, 2013).

Ostrowska *et al.* have recorded the synthesis of 11 coumarin-derived products, herein symbolized as **N83-N93** (Figure 6), by using a microwave-accelerated technique. The antitumor activity of these products was assayed versus two cancerous line cells named DU145 and B16F10. The results indicated that these products showed an encouraging cytotoxicity against the test cell lines, and this effect was dependent on the molecular lipophilic character (Ostrowska *et al.*, 2015).



**Figure 6.** Chemical structures of coumarin-derived products investigated by Ostrowska *et al.* as antitumor agents


Goel *et al.* have reported the synthesis of a series consists of 11 conjugates, herein symbolized as





**N94-N104** (Figure 7). These products were prepared by coupling two active moieties including hymecromone and midazo [1,2- $\alpha$ ] pyrazine. Their anticancer activity was evaluated versus 60 cancerous lines, which are belonged to the following cancer phenotypes: Leukemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal,

prostate, and breast. The results exhibited that the prepared conjugates have a broad antitumor activity versus the test cancerous lines, and there is a significant correlation between this potential and the lipophilicity of the tested products (Goel et al., 2015).



181

**Figure 7.** Chemical backbones of hymecromone-midazo[1,2- $\alpha$ ] pyrazine conjugates prepared by Goel *et al.*

Hejchman *et al.* have reported the synthesis of 14 Schiff bases using hymecromone as a core structure. These bases, herein symbolized as **N105-N118** (Figure 8), have been evaluated as anticancer agents versus two cancerous lines including CFPAC-1 (pancreas cancer) and HeLa (cervical cancer) cells. Among the prepared bases,

compounds **N109-N111** showed a potent cytotoxicity against the test line cells. The author concluded that the presence of a small electron-donating group in the para position to the nitrogen side of the Schiff base may enhance the antiproliferative potential of the prepared products (Hejchman et al., 2019).







Figure 8. Chemical backbones of the coumarinyl-Schiff bases synthesized by Heichman *et al.*

Jawoor *et al.* have prepared a Schiff base derived from hymecromone, as shown in Scheme 4. The resulted base, herein symbolized as **N119**, acts as a ligand that was complexed separately with Co(II), Ni(II), and Cu(II). The cytotoxicity of the ligand and

its prepared complexes was evaluated versus PC-1 (ovarian cancer) cells. The results revealed that the prepared products were non-toxic to the tested cancerous line cells (Jawoor *et al.*, 2018).




Scheme 4. Synthetic plan of the Schiff-base derived from hymecromone and prepared by Jawoor *et al.*






Lokeshwa *et al.* have examined the cytotoxic mechanism of hymecromone by studying its potential on several prostatic cancerous lines including PC3-ML, DU145, C4-2B, LNCaP, and LAPC-4 cells. The results exhibited that the cytotoxic effects of hymecromone including the inhibition of proliferation and invasion are mediated from the ability of this synthetic coumarin to inhibit the synthesis of HA (Lokeshwar *et al.*, 2010).

Naik *et al.* have reported the preparation of eight new coumarinyl-mustard conjugates, as shown in Scheme 5. The antitumor potential of these conjugates, herein symbolized as **N120-N127**, was screened on two cancerous lines, which are HeLa and MCF-7 cells. The results exhibited that the synthesized products have a potent antitumor potential with a notability attributed to products **N124** and **N125** (MV, 2017).



**Scheme 5.** Synthetic plan of the coumarinyl-mustard conjugates prepared by Naik *et al.*

Manidhar *et al.* have reported the synthesis of nine hymecromone-derived products substituted at position 8 with various functional groups. The binding capability of these products, herein symbolized as **N128-N136** (Figure 9), to the active site of Human PDE 4B was investigated. The target protein plays a fundamental role in the initiation and invasion of various cancer phenotypes. The results exhibited that the prepared products showed a high affinity to the target protein with a notability contributed to product **N135**. The authors concluded that these products offered a significant template to design new agents for targeting this essential protein affording a better chemotherapeutic effect (Mark *et al.*, 2013).



**Figure 9.** Chemical structures of hymecromone-derived products prepared by Manidhar *et al.*

Miri *et al.* have investigated the antitumor activity of previously prepared 26 coumarin-derived products, herein symbolized as **N137-162**




(Figure 10), against three human cancerous lines including LS180 (colon adenocarcinoma), MCF-7 (breast adenocarcinoma), and K562 (chronic myelogenous leukemia). The results indicated that the subgroup having two hydroxy groups at positions 7 and 8, and also bearing at C3 position alkyl groups showed the best antitumor activity. This subgroup was followed by that category having two hydroxy groups substituted at positions 7 and 8, and also bearing at C3 position ethoxy-carbonyl ethyl or ethoxy-carbonyl methyl moiety. The authors proposed that these results may support reporting the SAR of hydroxycoumarins as probable antitumor agents (Miri et al., 2016).

| Structures |      | Substitutions  |  |  |
|------------|------|----------------|--|--|
|            |      | R <sup>1</sup> | R <sup>2</sup>                                     | R <sup>3</sup>                                     |
|            | N137 | H              | CH <sub>2</sub> CH <sub>3</sub>                    |  |
|            | N138 | H              | n-C <sub>6</sub> H <sub>13</sub>                   |  |
|            | N139 | H              | n-C <sub>10</sub> H <sub>21</sub>                  |  |
|            | N140 | H              | CH <sub>2</sub> CO <sub>2</sub> Et                 |  |
|            | N141 | Ac             | CH <sub>2</sub> CO <sub>2</sub> Et                 |  |
|            | N142 | Ac             | CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Et |  |
|            | N143 | H              | H  | H  |
|            | N144 | H              | H  | C <sub>2</sub> H <sub>5</sub>                      |
|            | N145 | H              | H  | n-C <sub>6</sub> H <sub>13</sub>                   |
|            | N146 | H              | H  | n-C <sub>10</sub> H <sub>21</sub>                  |
|            | N147 | H              | H  | CH <sub>2</sub> CO <sub>2</sub> Et                 |
|            | N148 | Ac             | Ac   | CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Et |
|            | N149 | Ac             | Ac   | H  |
|            | N150 | Ac             | Ac   | CH <sub>2</sub> CO <sub>2</sub> Et                 |
|            | N151 | Me             | Me   | CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Et |
|            | N152 | R <sup>1</sup> | R <sup>2</sup>                                     | R <sup>3</sup>                                     |
|            | N153 | H              | H  | CH <sub>2</sub> CO <sub>2</sub> Et                 |
|            | N154 | H              | H  | CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Et |
|            | N155 | Ac             | Ac   | CH <sub>2</sub> CO <sub>2</sub> Et                 |
|            | N156 | H              | H  |  |
|            | N157 | Me             | CH <sub>2</sub> CO <sub>2</sub> Et                 |  |
|            | N158 | Me             | CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Et |  |
|            | N159 | H              | Me   |  |
|            | N160 | H              | n-C <sub>3</sub> H <sub>7</sub>                    |  |
|            | N161 | Ac             | n-C <sub>3</sub> H <sub>7</sub>                    |  |
|            | N162 |                |  |  |

**Figure 10.** Chemical structures of coumarin-derived products investigated for their antitumor activity by Miri *et al.*

Shah *et al.* have reported the synthesis of five coumarinyl-oxy-acetamides starting from hymecromone. The antitumor potential of these products, herein symbolized as **N163-N167** (Figure 11), was examined against two cancerous

lines including A549 (lung cancer) and A375 (melanoma) cells. The results exhibited that product **N164** showed a better activity versus the A549 line than the other synthesized products, while **N167** is the best in consideration with the A375 cancerous line (Shah *et al.*, 2016).



| Compound | -NR <sup>1</sup> R <sup>2</sup> |
|----------|---------------------------------|
| N163     |                                 |
| N164     |                                 |
| N165     |                                 |
| N166     |                                 |
| N167     |                                 |

**Figure 11.** Chemical structures of coumarinyl-oxy-acetamides prepared by Shah *et al.*

### Conclusion

The various bioactivities and wide distribution of natural coumarin-based compounds have excited the researchers to synthesize many related products and investigate their biopotentials. Concerning the anticancer activity, there are plentiful reports which studied the structural characteristic features of hymecromone-based products as agents for fighting different cancer types. This review, after analyzing a high number of related scientific papers, concluded that the hymecromone could represent a potential template to construct new based agents with a better bioactivity and selectivity. The most important structural features of the hymecromone template that can be used to improve its antitumor potential include the presence of a small electron-donating group at position 5, long carbon-chain at position 8, and secondary amine linked by a short carbon-chain to position 3.



## References

- Küpeli Akkol E, Genç Y, Karpuz B, Sobarzo-Sánchez E, Capasso R. Coumarins and coumarin-related compounds in pharmacotherapy of cancer. *Cancers* 2020; 12(7): 1959.
- Aldewachi H, Mustafa YF, Najm R, Ammar F. Adulteration of slimming products and its detection methods. *Systematic Reviews in Pharmacy* 2020; 11(3): 289-296.
- Bashir MK, Mustafa YF, Oglah MK. Antitumor, antioxidant, and antibacterial activities of glycosylconjugated compounds: A review. *Systematic Reviews in Pharmacy* 2020; 11(4): 175-187.
- Bashir MK, Mustafa YF, Oglah MK. Synthesis and antitumor activity of new multifunctional coumarins. *Period Tche Quim* 2020; 17(36): 871-883.
- Bashir MK, Oglah MK, Mustafa YF. The Effect of Aryl And Heteroaryl Conjugation on the Biological Activities of Naphthalenes: A Review. *Annals of the Romanian Society for Cell Biology* 2021; 25(4): 13355-13379.
- Benitez A, Yates TJ, Shamaldevi N, Bowen T, Lokeshwar VB. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. *The Journal of urology* 2013; 190(1): 285-290.
- Bhattacharyya SS, Paul S, Mandal SK, Banerjee A, Boujedaini N, Khuda-Bukhsh AR. A synthetic coumarin (4-methyl-7 hydroxy coumarin) has anti-cancer potentials against DMBA-induced skin cancer in mice. *European journal of pharmacology* 2009; 614(1-3): 128-136.
- Goel R, Luxami V, Paul K. Synthesis, in vitro anticancer activity and SAR studies of arylated imidazo [1, 2-a] pyrazine-coumarin hybrids. *RSC Advances* 2015; 5(47): 37887-37895.
- Hejchman E, Kruszewska H, Maciejewska D, Sowirka-Taciak B, Tomczyk M, Sztokfisz-Ignasiak A, Młynarczyk-Biały I. Design, synthesis, and biological activity of Schiff bases bearing salicyl and 7-hydroxycoumarinyl moieties. *Monatshfte für Chemie-Chemical Monthly* 2019; 150(2): 255-266.
- Jawoor SS, Patil SA, Toragalmath SS. Synthesis and characterization of heteroleptic Schiff base transition metal complexes: a study of anticancer, antimicrobial, DNA cleavage and anti-TB activity. *Journal of Coordination Chemistry* 2018; 71(2): 271-283.
- Jumal J, Ibrahim DM, Harun FW. Evaluation of antitumor activity of copper complexes of coumarin in breast and lung cancer. *Middle-East Journal of Scientific Research* 2015; 23(12): 2946-51.
- Kawase M, Sakagami H, Motohashi N, Hauer H, Chatterjee SS, Spengler G, Molnár J. Coumarin derivatives with tumor-specific cytotoxicity and multidrug resistance reversal activity. *in vivo* 2005; 19(4): 705-711.
- Khalil RR, Mustafa YF. Phytochemical, antioxidant and antitumor studies of coumarins extracted from Granny Smith apple seeds by different methods. *Systematic Reviews in Pharmacy* 2020; 11(2): 57-63.
- Kumar KA, Renuka N, Pavithra G, Kumar GV. Comprehensive review on coumarins: Molecules of potential chemical and pharmacological interest. *Journal of Chemical and Pharmaceutical Research* 2015; 7(9): 67-81.
- Li YJ, Wang CY, Ye MY, Yao GY, Wang HS. Novel coumarin-containing aminophosphonates as antitumor agent: synthesis, cytotoxicity, DNA-binding and apoptosis evaluation. *Molecules* 2015; 20(8): 14791-14809.
- Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Altman N. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. *Cancer research* 2010; 70(7): 2613-2623.
- Mahmood AAJ, Mustafa YS, Abdulstaar M. New coumarinic azo-derivatives of metoclopramide and diphenhydramine: Synthesis and in vitro testing for cholinesterase inhibitory effect and protection ability against chlorpyrifos. *IJUM Medical Journal Malaysia* 2014; 13(1): 3-12.
- Manidhar DM, Kesharwani RK, Reddy NB, Reddy CS, Misra K. Designing, synthesis, and characterization of some novel coumarin derivatives as probable anticancer drugs. *Medicinal Chemistry Research* 2013; 22(9): 4146-4157.
- Miri R, Nejati M, Saso L, Khakdan F, Parshad B, Mathur D, Firuzi O. Structure-activity relationship studies of 4-methylcoumarin derivatives as anticancer agents. *Pharmaceutical biology* 2016; 54(1): 105-110.
- Mohammed ET, Mustafa YF. Coumarins from Red Delicious apple seeds: Extraction, phytochemical analysis, and evaluation as antimicrobial agents. *Systematic Reviews in Pharmacy* 2020; 11(2): 64-70.
- Musa MA, Latinwo LM, Joseph MY, Badisa VL. Identification of 7, 8-diacetoxy-3-arylcoumarin derivative as a selective cytotoxic and apoptosis-inducing agent in a human prostate cancer cell line. *Anticancer research* 2017; 37(11): 6005-6014.
- Mustafa YF. Synthesis, characterization and preliminary cytotoxic study of sinapic acid and its analogues. *Journal of Global Pharma Technology* 2019; 11(9): 1-10.
- Mustafa YF, Abdulaziz NT. A Review on the Antineoplastic Activity of Hymecromone and its Based Products. *Annals of the Romanian Society for Cell Biology* 2021: 13339-13354.
- Mustafa YF, Abdulaziz NT. Hymecromone and Its Derivatives as Promising Cytotoxic Agents: A Review. *Annals of the Romanian Society for Cell Biology* 2021; 25(3): 6974-6981.
- Mustafa YF, Abdulaziz NT, Khalil RR, Mohammed ET, Oglah MK, Bashir MK, Marooqi MA. A Review on the Folate-Linked Prodrugs for Cancer Chemotherapy. *Annals of the Romanian Society for Cell Biology* 2021; 25(4): 5645-5670.
- Mustafa YF, Abdulaziz NT, Jasima MH. 4-Methylumbelliferone and its derived compounds: A brief review of their cytotoxicity. *Egyptian Journal of Chemistry* 2021b; 64(4): 1807-1816.
- Mustafa YF, Bashir MK, Oglah MK. Original and innovative advances in the synthetic schemes of coumarin-based derivatives: A review. *Systematic Reviews in Pharmacy* 2020; 11(6): 598-612.
- Mustafa YF, Khalil RR, Mohammed ET. Antimicrobial activity of aqueous extracts acquired from the seeds of two apples' cultivars. *Systematic Reviews in Pharmacy* 2020; 11(2): 382-387.
- Mustafa YF, Mohammed ET, Khalil RR. Antioxidant and Antitumor Activities of Methanolic Extracts Obtained from Red Delicious and Granny Smith Apples' Seeds. *Systematic Reviews in Pharmacy* 2020; 11(4): 570-576.
- Mustafa YF, Najem MA, Tawffiq ZS. Coumarins from Creston apple seeds: Isolation, chemical modification, and cytotoxicity study. *Journal of Applied Pharmaceutical Science* 2018; 8(8): 49-56.
- Mustafa YF, Oglah MK, Bashir MK. Conjugation of sinapic acid analogues with 5-Fluorouracil: Synthesis, preliminary



- cytotoxicity, and release study. *Systematic Reviews in Pharmacy* 2020; 11(3): 482-489.
- Mustafa YF, Oglah MK, Bashir MK, Mohammed ET, Khalil RR. Prodrug of 5-Fluorouracil and 5-Ethynyluracil: Synthesis, Characterization, and Release Study. *Annals of the Romanian Society for Cell Biology* 2021; 25(4): 5671-5688.
- MV K. 4-((Bis (2-Chloroethyl) Amino) Methyl)-2H-Chromen-2-Ones as Antifungal, Cytotoxic, Anti-tubercular and Antimicrobial Agents. *Modern Approaches in Drug Designing* 2017; 1(3): 1-10.
- Nejres AM, Ali HK, Behnam SP, Mustafa YF. Potential effect of ammonium chloride on the optical physical properties of polyvinyl alcohol. *Systematic Reviews in Pharmacy* 2020; 11(6): 726-732.
- Nejres AM, Mustafa YF, Aldewachi HS. Evaluation of natural asphalt properties treated with egg shell waste and low density polyethylene. *International Journal of Pavement Engineering* 2020: 1-7.
- Oglah MK, Bashir MK, Mustafa YF, Mohammed ET, Khalil RR. Synthesis and biological activities of 3, 5-disubstituted-4-hydroxycinnamic acids linked to a functionalized coumarin. *Systematic Reviews in Pharmacy* 2020; 11(6): 717-725.
- Oglah MK, Mustafa YF. Curcumin analogs: synthesis and biological activities. *Medicinal Chemistry Research* 2020; 29(3): 479-486.
- Oglah MK, Mustafa YF. Synthesis, antioxidant, and preliminary antitumor activities of new curcumin analogues. *Journal of Global Pharma Technology* 2020; 12(2): 854-862.
- Oglah MK, Mustafa YF, Bashir MK, Jasim MH, Mustafa YF. Curcumin and its derivatives: A review of their biological activities. *Systematic Reviews in Pharmacy* 2020; 11(3): 472-481.
- Ostrowska K. Coumarin-piperazine derivatives as biologically active compounds. *Saudi Pharmaceutical Journal* 2020; 28(2): 220-232.
- Ostrowska K, Hejchman E, Maciejewska D, Włodarczyk A, Wojnicki K, Matosiuk D, Dobrzycki Ł. Microwave-assisted preparation, structural characterization, lipophilicity, and anti-cancer assay of some hydroxycoumarin derivatives. *Monatshefte für Chemie-Chemical Monthly* 2015; 146(1): 89-98.
- Prabhu S, Jainu M, Sabitha KE, Devi CS. Cardioprotective effect of mangiferin on isoproterenol induced myocardial infarction in rats.. *Indian Journal of Experimental Biology* 2006; 44(3): 209-215.
- Saito T, Tamura DAI, Nakamura T, Makita Y, Ariyama H, Komiyama K, Asano R. 4-methylumbelliferone leads to growth arrest and apoptosis in canine mammary tumor cells. *Oncology reports* 2013; 29(1): 335-342.
- Shah NN, Soman SS, Buch P, Balkrishnan S. Synthesis and anticancer activity of some new 2-[(4-methy-2-oxo-2H-chromen-7-yl)-oxy] acetamide derivatives. *Der Pharma Chemica* 2016; 8(1): 397-403.
- Tao A, Song Z, Feng X, Hu B, Lei X. Magnolol-Coumarin-Phenylbutyric acid Conjugates: An Anticancer Prodrug via multiple targets. In *IOP Conference Series: Earth and Environmental Science* 2019; 330(4): 042054.
- Yelchuri V, RBN P, Karuna MS, Poornachandra Y, Kumar CG. Synthesis of Novel Fatty Substituted 4-methyl-2H-Chromen-2-one via Cross Metathesis: Potential Antioxidants and Chemotherapeutic Agents. *Journal of oleo science* 2016; 65(12): 1023-1031.
- Zheng J, Zhou Y. Brain-computer interface data classification based on support vector machine. *NeuroQuantology* 2018; 16(6): 638-642.

